Please use this identifier to cite or link to this item:
Title: Extracorporeal shockwave lithotripsy could lead to a prolonged increase in the renal fibrotic process of up to 2 years
Authors: Ng, CF
Luke, S
Yee, CH
Leung, SCH
Teoh, JYC
Yuen, J 
Keywords: Extracorporeal shockwave lithotripsy
Renal fibrosis
Issue Date: 2018
Publisher: Mary Ann Liebert Inc.
Source: Journal of endourology, 2018, v. 32, no. 3, p. 223-229 How to cite?
Journal: Journal of endourology 
Abstract: Introduction and Objective: This prospective study aimed to evaluate the effect of ramping and pause protocols on renal fibrosis, blood pressure control, and renal function in patients receiving extracorporeal shockwave lithotripsy (SWL). Patients and Methods: This study prospectively recruited 320 patients with solitary radiopaque renal stones <15 mm in size. Patients were randomized to receive one of four shockwave protocols: (1) standard protocol (no ramping or pause); (2) ramping protocol alone; (3) ramping and pause protocols; or (4) pause protocol alone. Spot urine samples were collected before and for 2 years after treatment to monitor the levels of the renal fibrosis marker procollagen III aminoterminal propeptide (PIIINP) by blinded research staffs. Blood pressure and serum creatinine levels were also monitored during follow-up. Results: The four groups had comparable baseline data and treatment parameters. Significant increases (p < 0.05) in the urinary PIIINP levels from 6 weeks until 18 months after SWL were observed among all patients and in individual groups. PIIINP levels peaked at 1 year after SWL and gradually decreased to the baseline at 2 years. At the 2-year follow-up point, the overall serum creatinine levels remained significantly elevated (76.21-80.01 μmol/L, p < 0.001). Twenty (9.95%) patients developed new-onset hypertension and another 43 (36.4%) experienced worsening blood pressure control. However, no differences were observed among the four treatment groups. Conclusions: SWL led to significant increases in renal fibrosis marker levels for up to 18 months after treatment. However, no differences in changes in renal fibrosis marker and serum creatinine levels and worsening of blood pressure control were observed with respect to the use of either ramping or pause treatment protocols.
ISSN: 0892-7790
DOI: 10.1089/end.2017.0684
Appears in Collections:Journal/Magazine Article

View full-text via PolyU eLinks SFX Query
Show full item record


Last Week
Last month
Citations as of Mar 29, 2019


Last Week
Last month
Citations as of Apr 8, 2019

Page view(s)

Citations as of Jul 16, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.